Combination therapy for first-line metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have metastatic colorectal cancer that cannot be surgically removed and has not been treated yet.
- Your tumor is microsatellite stable (MSS) or has normal mismatch repair (pMMR).
- You have at least one tumor that can be measured on scans (per RECIST 1.1).
- You are in good general health (ECOG score 0 or 1) and expected to live at least 12 weeks.
- Your blood counts, liver and kidney function, and clotting are within normal limits, and you have no active infections or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (HRS-2189) combined with two other medications (Adebrelimab and BP102) for people whose colorectal cancer has spread. It aims to see if this combination can help control the cancer.
This trial tests a mix of three drugs (sintilimab, bevacizumab, and decitabine) for people with advanced colorectal cancer that has a stable or low amount of genetic change. It’s for those whose cancer has grown after at least two prior treatments, and who have not had immunotherapy before.
This trial tests a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus chemotherapy for people with a specific type of colorectal cancer that hasn't spread to the liver. It may be an option if your cancer is mismatch repair stable (MSS or pMMR) and has progressed after initial treatment.
This trial tests whether combining two drugs—bevacizumab and adebrelimab—can help people with a specific type of colorectal cancer that has spread and is MSS-type. It's for patients who have already had standard chemotherapy and have tumors that show certain genetic features.
This trial is testing a combination of three drugs (liposomal irinotecan, capecitabine, and bevacizumab) for people with metastatic colorectal cancer whose first-line treatment failed. The goal is to see if this combo works better as a second option.
This study tests a combination of several cancer drugs (irinotecan, capecitabine, bevacizumab, and camrelizumab) in people with metastatic colorectal cancer who have already tried at least one prior treatment. The goal is to see if these drugs work better together for patients who don't have certain genetic features.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.